Early results from phase 1 and 2 studies are also showing encouraging efficacy with isocitrate dehydrogenase inhibitors (ivosidenib and enasidenib) as monotherapy in patients with IDH1/2-mutated high-risk MDS [89, 90, 98]. This evidence concerns the gene IDH1 and myelodysplastic syndrome.